Lead sponsor
Shanghai Zhongshan Hospital
8 GLP-1 and incretin trials led. Source: ClinicalTrials.gov, as of July 1, 2026.
8
Trials led
5
Active
2,614
Total enrollment
15
Sites
Distinct sites across this sponsor's lead trials. A site running several of them counts once, matching the map. Total enrollment sums each trial's reported enrollment, whether planned or actual.
Portfolio
How this sponsor's trials break down
Trials by phase
Phase 1/2
1
Phase 2
2
Phase 3
1
Phase 4
2
Not applicable
2
Trials by status
Not yet recruiting
2
Recruiting
3
Completed
2
Unknown
1
Trials led
TrialKey I/E criterionPhaseStatusEnrollment
Efficacy and Safety of iGlarLixi Versus Standard of Care in a Real-world Adult China Population With Uncontrolled Type 2 Diabetes on Oral AgentsHbA1c 7.5-11%Ph 4Not yet recruiting1,316
ASCEND-1: Lifestyle Intervention Plus Mazdutide for Weight ManagementBMI 28-45not applicableRecruiting420
The Efficacy and Safety of Liraglutide on Body Weight Loss in Obese and Overweight PatientsBMI ≥30Ph 3Completed414
PEG-rhGH and Semaglutide Combination Therapy in Non-Diabetic Obese AdultsBMI ≥28Ph 4Not yet recruiting212